New curcumin analog, CCA-1.1, synergistically improves the antiproliferative effect of doxorubicin against T47D breast cancer cells

An improved compound of pentagamavunone-1 (PGV-1), chemoprevention-curcumin analog 1.1 (CCA-1.1), has been synthesized and proven to have antiproliferative effects against breast cancer cells. This study is designed to investigate the potency of CCA-1.1 alone and in combination with doxorubicin (Dox...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Febri Wulandari, Muthi' Ikawati, Dhania Novitasari, Mitsunori Kirihata, Jun-ya Kato, Edy Meiyanto
Formato:	article
Lenguaje:	EN
Publicado:	Universitas Gadjah Mada 2020
Materias:	cell cycle apoptosis t47d cells breast cancer new curcumin analog (cca-1.1) Pharmacy and materia medica RS1-441
Acceso en línea:	https://doaj.org/article/9b3e16eefe9341d78d2a4662424780b0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9b3e16eefe9341d78d2a4662424780b0
record_format	dspace
spelling	oai:doaj.org-article:9b3e16eefe9341d78d2a4662424780b02021-11-15T06:08:47ZNew curcumin analog, CCA-1.1, synergistically improves the antiproliferative effect of doxorubicin against T47D breast cancer cells2338-94272338-948610.22146/ijp.681https://doaj.org/article/9b3e16eefe9341d78d2a4662424780b02020-12-01T00:00:00Zhttps://jurnal.ugm.ac.id/v3/IJP/article/view/681https://doaj.org/toc/2338-9427https://doaj.org/toc/2338-9486An improved compound of pentagamavunone-1 (PGV-1), chemoprevention-curcumin analog 1.1 (CCA-1.1), has been synthesized and proven to have antiproliferative effects against breast cancer cells. This study is designed to investigate the potency of CCA-1.1 alone and in combination with doxorubicin (Dox) on T47D cells in comparison with that of PGV-1. We used the MTT assay to assess cytotoxic activity. Propidium iodide (PI), annexin-V–PI, and DCFDA staining were respectively used to determine cell cycle profiles, apoptosis, and intracellular reactive oxygen species (ROS) levels. Senescent cells were identified using the SA-b-galactosidase assay. Our results revealed that CCA-1.1 possesses cytotoxic effects similar to those of PGV-1 on T47D cells. Synergistic effects during co-treatment with Dox were also observed. CCA-1.1 arrested cell cycle progression at the G2/M phase and limited sub-G1 accumulation, which is correlated with apoptosis. CCA-1.1 alone and in combination with Dox increased senescence and intracellular ROS to a similar level to those achieved by PGV-1. CCA-1.1 alone and in combination with Dox enhanced cytotoxic activity toward T47 cells compared to PGV-1. Thus, this curcumin analog may be a potential chemotherapeutic/co-chemotherapeutic candidate for estrogen receptor-positive (ER+) breast cancer therapy.Febri WulandariMuthi' IkawatiDhania NovitasariMitsunori KirihataJun-ya KatoEdy MeiyantoUniversitas Gadjah Madaarticlecell cycleapoptosist47d cellsbreast cancernew curcumin analog (cca-1.1)Pharmacy and materia medicaRS1-441ENIndonesian Journal of Pharmacy, Pp 244-256 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	cell cycle apoptosis t47d cells breast cancer new curcumin analog (cca-1.1) Pharmacy and materia medica RS1-441
spellingShingle	cell cycle apoptosis t47d cells breast cancer new curcumin analog (cca-1.1) Pharmacy and materia medica RS1-441 Febri Wulandari Muthi' Ikawati Dhania Novitasari Mitsunori Kirihata Jun-ya Kato Edy Meiyanto New curcumin analog, CCA-1.1, synergistically improves the antiproliferative effect of doxorubicin against T47D breast cancer cells
description	An improved compound of pentagamavunone-1 (PGV-1), chemoprevention-curcumin analog 1.1 (CCA-1.1), has been synthesized and proven to have antiproliferative effects against breast cancer cells. This study is designed to investigate the potency of CCA-1.1 alone and in combination with doxorubicin (Dox) on T47D cells in comparison with that of PGV-1. We used the MTT assay to assess cytotoxic activity. Propidium iodide (PI), annexin-V–PI, and DCFDA staining were respectively used to determine cell cycle profiles, apoptosis, and intracellular reactive oxygen species (ROS) levels. Senescent cells were identified using the SA-b-galactosidase assay. Our results revealed that CCA-1.1 possesses cytotoxic effects similar to those of PGV-1 on T47D cells. Synergistic effects during co-treatment with Dox were also observed. CCA-1.1 arrested cell cycle progression at the G2/M phase and limited sub-G1 accumulation, which is correlated with apoptosis. CCA-1.1 alone and in combination with Dox increased senescence and intracellular ROS to a similar level to those achieved by PGV-1. CCA-1.1 alone and in combination with Dox enhanced cytotoxic activity toward T47 cells compared to PGV-1. Thus, this curcumin analog may be a potential chemotherapeutic/co-chemotherapeutic candidate for estrogen receptor-positive (ER+) breast cancer therapy.
format	article
author	Febri Wulandari Muthi' Ikawati Dhania Novitasari Mitsunori Kirihata Jun-ya Kato Edy Meiyanto
author_facet	Febri Wulandari Muthi' Ikawati Dhania Novitasari Mitsunori Kirihata Jun-ya Kato Edy Meiyanto
author_sort	Febri Wulandari
title	New curcumin analog, CCA-1.1, synergistically improves the antiproliferative effect of doxorubicin against T47D breast cancer cells
title_short	New curcumin analog, CCA-1.1, synergistically improves the antiproliferative effect of doxorubicin against T47D breast cancer cells
title_full	New curcumin analog, CCA-1.1, synergistically improves the antiproliferative effect of doxorubicin against T47D breast cancer cells
title_fullStr	New curcumin analog, CCA-1.1, synergistically improves the antiproliferative effect of doxorubicin against T47D breast cancer cells
title_full_unstemmed	New curcumin analog, CCA-1.1, synergistically improves the antiproliferative effect of doxorubicin against T47D breast cancer cells
title_sort	new curcumin analog, cca-1.1, synergistically improves the antiproliferative effect of doxorubicin against t47d breast cancer cells
publisher	Universitas Gadjah Mada
publishDate	2020
url	https://doaj.org/article/9b3e16eefe9341d78d2a4662424780b0
work_keys_str_mv	AT febriwulandari newcurcuminanalogcca11synergisticallyimprovestheantiproliferativeeffectofdoxorubicinagainstt47dbreastcancercells AT muthiikawati newcurcuminanalogcca11synergisticallyimprovestheantiproliferativeeffectofdoxorubicinagainstt47dbreastcancercells AT dhanianovitasari newcurcuminanalogcca11synergisticallyimprovestheantiproliferativeeffectofdoxorubicinagainstt47dbreastcancercells AT mitsunorikirihata newcurcuminanalogcca11synergisticallyimprovestheantiproliferativeeffectofdoxorubicinagainstt47dbreastcancercells AT junyakato newcurcuminanalogcca11synergisticallyimprovestheantiproliferativeeffectofdoxorubicinagainstt47dbreastcancercells AT edymeiyanto newcurcuminanalogcca11synergisticallyimprovestheantiproliferativeeffectofdoxorubicinagainstt47dbreastcancercells
_version_	1718428569214910464

New curcumin analog, CCA-1.1, synergistically improves the antiproliferative effect of doxorubicin against T47D breast cancer cells

Ejemplares similares